MorphoSys AG Reports First Quarter 2024 Financial Results

EQS-News: MorphoSys AG / Key word(s): Quarterly / Interim StatementMorphoSys AG Reports First Quarter 2024 Financial Results 29.04.2024 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, April 29, 2024 MorphoSys AG Reports First Quarter 20...

Related Keywords

Planegg ,Bayern ,Germany ,Canada ,Massachusetts ,United States ,Boston ,Austria ,America ,German ,American ,Monjuvi Minjuvi ,Julia Neugebauer ,Eamonn Nolan ,Jean Paul Kress ,Thomas Biegi ,Linkedin ,Distribution Services ,Incyte Corporation ,Twitter ,Morphosys Group Key Figures ,Corporate Affairs ,Novartis ,Drug Administration ,European Medicines Agency ,American Society Of Clinical Oncology ,German Federal Financial Supervisory Authority The Bafin ,Lymphoma Society ,Company Annual Report On Form ,Constellation Pharmaceuticals Inc ,Group Revenues ,Exchange Commission ,Share Of Loss Associates ,Additional Group ,Xencor Inc ,Nasdaq ,Development Rd Expenses ,Corporate Communications Investor Relations ,Interim Statement ,First Quarter ,Business Combination Agreement ,Management Board ,Supervisory Board ,Chief Executive Officer ,Public Takeover Offer Highlights ,Novartis Bidco ,Morphosys Management Board ,Conferences Highlights ,Clinical Oncology ,Net Loss ,Discontinued Operations ,New Drug Application ,Marketing Authorization Application ,Sys Group Key Figures ,Impairment Losses ,Tax Benefit ,Net Profit ,Investor Relations ,Morphosys Investor Relations ,Antibody Dependent Cell Mediated Cytotoxicity ,Antibody Dependent Cellular Phagocytosis ,Prescribing Information ,German Federal Financial Supervisory Authority ,American Depositary Shares ,Tender Offer Statement ,Takeover Offer ,Takeover Offer Documents ,German Securities Acquisition ,Takeover Act ,Recommendation Statement ,Recommendation Statements ,Annual Report ,Vice President ,Global Investor ,Corporate Communications ,Corporate News ,Regulatory Announcements ,